Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Tax Provisions: 2017-2025

Historic Tax Provisions for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to -$407,000.

  • Organogenesis Holdings' Tax Provisions rose 93.75% to -$407,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 146.95%. This contributed to the annual value of $7.1 million for FY2024, which is 29.45% up from last year.
  • Latest data reveals that Organogenesis Holdings reported Tax Provisions of -$407,000 as of Q3 2025, which was up 83.33% from -$2.4 million recorded in Q2 2025.
  • Over the past 5 years, Organogenesis Holdings' Tax Provisions peaked at $13.3 million during Q4 2024, and registered a low of -$32.1 million during Q4 2021.
  • Its 3-year average for Tax Provisions is $246,273, with a median of -$1.2 million in 2023.
  • Data for Organogenesis Holdings' Tax Provisions shows a peak YoY increase of 1,703.70% (in 2021) and a maximum YoY decrease of 8,207.58% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Tax Provisions stood at -$32.1 million in 2021, then surged by 103.95% to $1.3 million in 2022, then slumped by 196.85% to -$1.2 million in 2023, then soared by 1,182.98% to $13.3 million in 2024, then spiked by 93.75% to -$407,000 in 2025.
  • Its Tax Provisions stands at -$407,000 for Q3 2025, versus -$2.4 million for Q2 2025 and -$6.9 million for Q1 2025.